Biontech Se Sponsored Adr Stock News

The FDA has expanded the emergency use authorization for Pfizer and BioNTechs Covid-19 booster shot to cover 16- and 17-year- olds, making it the only booster available in the U.S.

Recipients of the BioNTech Covid-19 vaccine should get their jabs on the thigh rather than arm to reduce heart inflammation risks, Hong Kong health experts have said, after a panel delivered its first indeterminate ruling on whether a death was linked to the shot.Advisers to the citys pandemic strategy said on Thursday that changing the injection site would make the German-made jab safer for all age groups, with one urging the government to make it standard practice for adolescents.The

With the U.S. Federal Reserve, European Central Bank and Bank of England among those meeting to discuss monetary policy next week, investors will be keenly watching for forward guidance, especially from the Fed, where some analysts expect a faster unwinding of pandemic-era stimulus plans. Some of the fears around the Omicron variant ebbed after BioNTech and Pfizer said three shots of their COVID-19 vaccine neutralised it in a laboratory test.

The CDC still needs to sign off on the boosters for teens.

The FDA has expanded the Emergency Use Authorization (EUA) of a booster dose of Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine to include individuals 16 years of age an

CNBC's Jim Cramer and the 'Squawk on the Street' team discuss new studies out of Israel looking at how well Pfizer and BioNTech's Covid-19 booster works in people over age 50.

The Food and Drug Administration said 16- and 17-year-olds can now get booster doses of BioNTech SE BNTX, -0.22% and Pfizer Inc.'s PFE, +2.41% COVID-19 vaccine. BioNTech's stock was down 0.1% in tradi

Redburn Head of Global Biopharma Research Simon Baker discusses the impact of the omicron variant on vaccine efficacy and the risk of hospitalization.

By Joice Alves London, Dec 9 (Reuters) The euro, sterling and dollar stabilised on Thursday amid hopes some COVID-19 vaccines might be able to neutralise new coronavirus variant Omicron. Analysts said the focus was shifting back to monetary policy. Some of the fears around the Omicron variant ebbed after BioNTech and Pfizer said three [] The post FOREX-Euro, dollar steady with Omicron fears and central appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .

Pfizer and BioNTech announced a three-shot course of Covid-19 vaccine was able to neutralise the new Omicron variant and can deliver an Omicron-based vaccine by March 2022. In an official statement on the efficacy of the dose, BioNTech and Pfizer said that two vaccine doses resulted in relatively low antibodies. The post BioNTech, Pfizer Vaccine Neutralises Omicron with 3 Doses appeared first on Equitypandit .

BioNTech (NASDAQ:BNTX) had its price objective upped by Bank of America from $341.00 to $349.00 in a research report report published on Monday, The Fly reports. They currently have a neutral rating on the stock. Other analysts have also recently issued reports about the stock. Jefferies Financial Group set a $230.00 price target on shares []

US drugmaker, Pfizer has said that its preliminary lab studies showed that three doses of the Pfizer/BioNTech COVID-19 vaccine can provide sufficient protection against the Omicron coronavirus variant. Pfizer alongside BioNTech in a statement on Wednesday said samples from people who had two doses of the COVID-19 vaccine showed on average, a more than 25-fold [] The post Vaccine maker, Pfizer, says three doses can sufficiently prevent COVID-19 Omicron variant appeared first on Latest Nigeria News | Top Stories from Ripples Nigeria .

Most Asian currencies firmed against the greenback on Thursday, led by the Thai baht and Malaysian ringgit, amid waning concerns about the economic impact of the Omicron coronavirus variant and a slowing Chinese factory-gate inflation. The Thai baht, the worst performing currency in the region, marked its third straight day in the black after it firmed 0.2% to 33.39 per dollar, its highest in two weeks. The Malaysian ringgit advanced slightly to a one-week peak. Indications that Omicron may not be as bad as feared and a slowing factory-gate inflation in China, Southeast Asia''s largest trading partner, supported risk appetite in the region. "This is fairly intuitive and expected in the context of (and exaggerated by) a harsh sell-off/risk off on Omicron last week, being met with encouraging news of early studies downplaying its severity and threat posed," analysts at Mizuho Bank said. BioNTech and Pfizer said a three-shot course of their COVID-19 vaccine was able to neutralise Omicron in a laboratory test, an indication that booster shots could be key to protection against the variant.

Wall Street closed slightly higher on Wednesday with the three major indexes managing their third straight day of gains after test data showed the COVID-19 vaccine from Pfizer and BioNTech offered some protection against the new Omicron variant. Pfizer and BioNTech said their three-shot course of the vaccine was able to neutralize the Omicron variant in a laboratory test and they could deliver an upgraded vaccine in March 2022 if needed. Investors on wall street

TOKYO: Japan''s Nikkei share average slipped on Thursday as investors turned cautious ahead of key central bank meetings next week, although strong gains for airlines limited losses with Omicron fears continuing to recede. The Nikkei 225 declined 0.15% to 28,818.53 as of the lunch break, but had earlier touched a nearly two-week intraday high of 28,908.29. The U.S. Federal Reserve headlines a string of central bank policy decisions next week, which also includes the Bank of Japan and European Central Bank. Investors seem to want to take time to judge the direction of financial markets with so many key central banks meetings next week, so they are adopting a wait-and-see approach, said Masahiro Ichikawa, chief market strategist at Sumitomo Mitsui DS Asset Management. The 200-day moving average is putting a tight lid on gains. The 200-day moving average provided stiff resistance at 28,895.39, as investors took a breather following a more than 4% rally from last Thursday''s close. The broader Topix sank 0.33%, with metal products , textiles and machinery stocks leading declines.